UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma

The oncologist (Dayton, Ohio), 2021-03, Vol.26 (3), p.e367-e373

2021

Volltextzugriff (PDF)

The impact of sodium‐glucose cotransporter‐2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer

Journal of gastroenterology and hepatology, 2024-05, Vol.39 (5), p.902-907

2024

Volltextzugriff (PDF)

Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Heart (British Cardiac Society), 2023-03, Vol.109 (6), p.470-477

2023

Volltextzugriff (PDF)

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors

Scientific reports, 2021-03, Vol.11 (1), p.4834-4834, Article 4834

2021

Volltextzugriff (PDF)

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations

Japanese journal of clinical oncology, 2022-12, Vol.52 (12), p.1389-1398

2022

Volltextzugriff (PDF)

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

British journal of cancer, 2020-04, Vol.122 (9), p.1324-1332

2020

Volltextzugriff (PDF)

Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy

Hepatology (Baltimore, Md.), 2011-10, Vol.54 (4), p.1199-1207

2011

Volltextzugriff (PDF)

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.417-431

2022

Volltextzugriff (PDF)

Chemopreventive effects of Xiang Sha Liu Jun Zi Tang on paclitaxel-induced leucopenia and neuropathy in animals

Frontiers in pharmacology, 2023-03, Vol.14, p.1106030-1106030

2023

Volltextzugriff (PDF)

Phase I Dose‐Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2021-04, Vol.26 (4), p.e567-e579

2021

Volltextzugriff (PDF)

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231183680-17588359231183680

2023

Volltextzugriff (PDF)

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

Journal of thoracic oncology, 2020-12, Vol.15 (12), p.1907-1918

2020

Volltextzugriff (PDF)

Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503

Molecular cancer therapeutics, 2006-10, Vol.5 (10), p.2484-2493

2006

Volltextzugriff (PDF)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression

Diagnostics (Basel), 2023-04, Vol.13 (9), p.1597

2023

Volltextzugriff (PDF)

Tn (N-acetyl-d-galactosamine-O-serine/threonine) immunization protects against hyperoxia-induced lung injury in adult mice through inhibition of the nuclear factor kappa B activity

International immunopharmacology, 2018-06, Vol.59, p.261-268

2018

Volltextzugriff (PDF)

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

Investigational new drugs, 2023-04, Vol.41 (2), p.306-316

2023

Volltextzugriff (PDF)

Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer

Cancers, 2020-11, Vol.12 (11), p.3394

2020

Volltextzugriff (PDF)

Effects of Dang-Gui-Bu-Xue-Tang, an herbal decoction, on iron uptake in iron-deficient anemia

Drug design, development and therapy, 2016-01, Vol.10 (Issue 1), p.949-957

2016

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma

Cancer chemotherapy and pharmacology, 2006-11, Vol.58 (5), p.654-664

2006

Volltextzugriff (PDF)

Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors

Free radical biology & medicine, 2011-12, Vol.51 (12), p.2195-2209

2011

Volltextzugriff (PDF)

Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent

Journal of clinical oncology, 2009-12, Vol.27 (36), p.e271; author reply e272-e271

2009

Volltextzugriff (PDF)

Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer

Journal of gastroenterology and hepatology, 2006-05, Vol.21 (5), p.874-879

2006

Volltextzugriff (PDF)

Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer

Journal of gastroenterology and hepatology, 2006-03, Vol.21 (3), p.531-536

2006

Volltextzugriff (PDF)

D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

Molecular cancer therapeutics, 2007-01, Vol.6 (1), p.193-202

2007

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBiochemical Pharmacology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(61)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Humans
(22)
Oncology
(17)
Male
(11)
Female
(10)
Tumors
(10)
Adult
(9)
Biological And Medical Sciences
(9)
Aged
(8)
Medical Sciences
(8)
Middle Aged
(8)
Patients
(8)
Pharmacology & Pharmacy
(6)
Animals
(5)
Chemotherapy
(5)
Fluorouracil - Administration & Dosage
(5)
Gastroenterology. Liver. Pancreas. Abdomen
(5)
Leucovorin - Administration & Dosage
(5)
Liver. Biliary Tract. Portal Circulation. Exocrine Pancreas
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma

The impact of sodium‐glucose cotransporter‐2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer

Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Chemopreventive effects of Xiang Sha Liu Jun Zi Tang on paclitaxel-induced leucopenia and neuropathy in animals

Phase I Dose‐Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression

Tn (N-acetyl-d-galactosamine-O-serine/threonine) immunization protects against hyperoxia-induced lung injury in adult mice through inhibition of the nuclear factor kappa B activity

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer

Effects of Dang-Gui-Bu-Xue-Tang, an herbal decoction, on iron uptake in iron-deficient anemia

Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma

Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors

Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent

Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer

Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer

D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

Aktive Filter

Suchergebnisse filtern